221 related articles for article (PubMed ID: 19617863)
1. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Ferris S; Nordberg A; Soininen H; Darreh-Shori T; Lane R
Pharmacogenet Genomics; 2009 Aug; 19(8):635-46. PubMed ID: 19617863
[TBL] [Abstract][Full Text] [Related]
2. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
3. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.
Lane R; He Y; Morris C; Leverenz JB; Emre M; Ballard C
Mov Disord; 2009 Feb; 24(3):392-400. PubMed ID: 19006190
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
5. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
8. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
9. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
[TBL] [Abstract][Full Text] [Related]
10. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.
Ferris S; Lane R; Sfikas N; Winblad B; Farlow M; Feldman HH
Gend Med; 2009 Jul; 6(2):345-55. PubMed ID: 19682661
[TBL] [Abstract][Full Text] [Related]
11. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
13. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
14. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
[TBL] [Abstract][Full Text] [Related]
15. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
16. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
17. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
[TBL] [Abstract][Full Text] [Related]
18. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
19. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
[TBL] [Abstract][Full Text] [Related]
20. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]